JP2018083821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018083821A5 JP2018083821A5 JP2017245743A JP2017245743A JP2018083821A5 JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5 JP 2017245743 A JP2017245743 A JP 2017245743A JP 2017245743 A JP2017245743 A JP 2017245743A JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid position
- substitution
- wild type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 35
- 150000001413 amino acids Chemical group 0.000 claims 35
- 238000006467 substitution reaction Methods 0.000 claims 27
- 238000000034 method Methods 0.000 claims 24
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 19
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 19
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 15
- 230000035772 mutation Effects 0.000 claims 11
- 102000001708 Protein Isoforms Human genes 0.000 claims 9
- 108010029485 Protein Isoforms Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 6
- 208000006994 Precancerous Conditions Diseases 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 5
- 235000004279 alanine Nutrition 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 208000007541 Preleukemia Diseases 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/418,242 US9175331B2 (en) | 2010-09-10 | 2012-03-12 | Inhibitors of human EZH2, and methods of use thereof |
| US13/418,242 | 2012-03-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Division JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018083821A JP2018083821A (ja) | 2018-05-31 |
| JP2018083821A5 true JP2018083821A5 (enExample) | 2018-07-12 |
| JP6592071B2 JP6592071B2 (ja) | 2019-10-16 |
Family
ID=47913638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Active JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
| JP2017245743A Active JP6592071B2 (ja) | 2012-03-12 | 2017-12-22 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Active JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2825161B1 (enExample) |
| JP (2) | JP6321619B2 (enExample) |
| KR (4) | KR102453519B1 (enExample) |
| CN (2) | CN110420327B (enExample) |
| AU (4) | AU2013232229B2 (enExample) |
| CA (2) | CA2867282C (enExample) |
| DK (1) | DK2825161T3 (enExample) |
| ES (1) | ES2718900T3 (enExample) |
| HU (1) | HUE042271T2 (enExample) |
| PL (1) | PL2825161T3 (enExample) |
| PT (1) | PT2825161T (enExample) |
| RU (2) | RU2704445C2 (enExample) |
| TR (1) | TR201904660T4 (enExample) |
| WO (1) | WO2013138361A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| PL3628670T3 (pl) | 2012-04-13 | 2023-02-20 | Epizyme, Inc. | Postać soli dla inhibicji ezh2 |
| WO2014049488A1 (en) * | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| SG10201705989YA (en) | 2012-10-15 | 2017-08-30 | Epizyme Inc | Substituted benzene compounds |
| MX376008B (es) * | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| SI3057962T1 (sl) | 2013-10-16 | 2024-01-31 | Epizyme, Inc. | Oblika hidrokloridne soli za ezh2 inhibicijo |
| AU2014337121A1 (en) * | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| KR20220165809A (ko) | 2013-12-06 | 2022-12-15 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| US20160361309A1 (en) * | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| PL3157527T3 (pl) * | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| MX384423B (es) | 2014-06-19 | 2025-03-14 | Memorial Sloan Kettering Cancer Center | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). |
| CA2963149A1 (en) * | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| ES2722048T3 (es) | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| WO2016172332A1 (en) * | 2015-04-22 | 2016-10-27 | The University Of North Carolina At Chapel Hill | A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| US20180321256A1 (en) | 2015-11-05 | 2018-11-08 | Epizyme, Inc. | Flow cytometry for monitoring histone h3 methylation status |
| CN109069508A (zh) * | 2016-04-22 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | Ezh2抑制剂及其用途 |
| WO2017201585A1 (en) * | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
| EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| EP3472161B1 (en) | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CA3044691A1 (en) | 2016-10-26 | 2018-05-03 | Genea Biocells USA (Holdings), Inc. | Improved generation of muscle lineage cells and therapeutic uses thereof |
| WO2018086592A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途 |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| KR102758037B1 (ko) | 2017-08-18 | 2025-01-22 | 코테라 바이오사이언스 인코포레이티드 | Tg02의 다형성 형태 |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| WO2019204998A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京肿瘤医院 | Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用 |
| KR102810863B1 (ko) * | 2018-06-03 | 2025-05-20 | 엑셀시오 파마테크 랩스 | 비-밀집 심근증 치료 방법 |
| EP3831822A4 (en) | 2018-07-27 | 2022-03-23 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | POLYSUBSTITUTED BENZENE COMPOUND AND METHOD FOR PREPARING IT AND ITS USE |
| WO2020219606A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN113024516B (zh) * | 2021-03-29 | 2022-05-17 | 中国药科大学 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
| US20240350508A1 (en) | 2021-08-25 | 2024-10-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119143880A (zh) * | 2024-09-20 | 2024-12-17 | 上海交通大学医学院附属第九人民医院 | 抗ezh2蛋白抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| ES2324435B1 (es) * | 2005-10-27 | 2010-05-31 | Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
| WO2008101118A2 (en) * | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2009124137A2 (en) * | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| PL2614369T3 (pl) * | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112014007603A2 (pt) * | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
-
2013
- 2013-03-12 EP EP13711265.2A patent/EP2825161B1/en active Active
- 2013-03-12 KR KR1020217018417A patent/KR102453519B1/ko active Active
- 2013-03-12 JP JP2015500523A patent/JP6321619B2/ja active Active
- 2013-03-12 CN CN201910052279.0A patent/CN110420327B/zh active Active
- 2013-03-12 CA CA2867282A patent/CA2867282C/en active Active
- 2013-03-12 AU AU2013232229A patent/AU2013232229B2/en not_active Ceased
- 2013-03-12 ES ES13711265T patent/ES2718900T3/es active Active
- 2013-03-12 KR KR1020147028560A patent/KR102267502B1/ko active Active
- 2013-03-12 RU RU2014141045A patent/RU2704445C2/ru active
- 2013-03-12 KR KR1020237033924A patent/KR20230145531A/ko not_active Ceased
- 2013-03-12 HU HUE13711265A patent/HUE042271T2/hu unknown
- 2013-03-12 WO PCT/US2013/030565 patent/WO2013138361A1/en not_active Ceased
- 2013-03-12 PL PL13711265T patent/PL2825161T3/pl unknown
- 2013-03-12 CN CN201380024734.7A patent/CN104540500B/zh active Active
- 2013-03-12 PT PT13711265T patent/PT2825161T/pt unknown
- 2013-03-12 EP EP18214827.0A patent/EP3536314A1/en not_active Withdrawn
- 2013-03-12 CA CA3177515A patent/CA3177515A1/en active Pending
- 2013-03-12 TR TR2019/04660T patent/TR201904660T4/tr unknown
- 2013-03-12 RU RU2019132222A patent/RU2019132222A/ru unknown
- 2013-03-12 KR KR1020227034498A patent/KR102587175B1/ko active Active
- 2013-03-12 DK DK13711265.2T patent/DK2825161T3/en active
-
2017
- 2017-12-22 JP JP2017245743A patent/JP6592071B2/ja active Active
-
2018
- 2018-02-19 AU AU2018201176A patent/AU2018201176A1/en not_active Abandoned
-
2019
- 2019-10-17 AU AU2019250181A patent/AU2019250181A1/en not_active Abandoned
-
2021
- 2021-04-07 AU AU2021202119A patent/AU2021202119A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018083821A5 (enExample) | ||
| JP2015511603A5 (enExample) | ||
| RU2014141045A (ru) | Ингибиторы ezh2 человека и способы их применения | |
| JP7504853B2 (ja) | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド | |
| Guasp et al. | The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B* 51 peptidome by differential subpeptidome processing | |
| AR128541A2 (es) | Métodos para modificar el punto isoeléctrico de anticuerpos mediante la sustitución de aminoácidos en la región de determinación de la complementariedad (cdr) | |
| US20220340663A1 (en) | Tumor mutational load | |
| JP2010519176A5 (enExample) | ||
| JP2018529698A5 (enExample) | ||
| US20130195843A1 (en) | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof | |
| JP2016020389A5 (enExample) | ||
| JP2016026215A5 (enExample) | ||
| JP2013518055A5 (enExample) | ||
| JP2015525208A5 (enExample) | ||
| EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
| IL273254B2 (en) | HLA type II-restricted T cell receptors against RAS | |
| KR20170090447A (ko) | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| JP2016508504A5 (enExample) | ||
| SI3079715T1 (en) | A mixture of peptides | |
| EP4329780A1 (en) | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same | |
| FI3448879T3 (fi) | Claudin-6 -peptidejä | |
| JP2025134788A (ja) | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ | |
| JP2015519355A5 (enExample) | ||
| JP2012518669A5 (enExample) |